Your KRAS Report Explained — What Each Mutation Actually Means
Your molecular report says "KRAS G12D" — or G12V, G12C, G12R, or wild-type. What does that mean for your treatment? This page decodes the biology, separates approved drugs from experimental research, and gives you 10 questions to ask your oncologist before any treatment decision.
Quick Answer — If You Have 30 Seconds
KRAS is the single most important biomarker in pancreatic cancer. About 90% of PDAC tumors carry a KRAS mutation — but "KRAS mutant" is not one thing. The exact variant (G12C, G12D, G12V, G12R, Q61, etc.) determines which drugs or trials may apply.
Three things to know right now:
(1) Only G12C has FDA-approved drugs — and even there, PDAC response is limited.
(2) G12D is the most common variant (~40% of PDAC) — pan-KRAS inhibitors are in trials, not yet approved.
(3) KRAS wild-type (5–10%) is not "better" — it points to other actionable targets (NRG1, BRAF, NTRK, HER2).
The real question is not "which drug?" — it is "which trial is currently open for my exact variant?" That is the checklist this page gives you.
The Common Misconception — and What Actually Matters
Myth: "KRAS is undruggable — there's no point testing it."
Reality: As of 2026, KRAS G12C has two FDA-approved inhibitors (sotorasib, adagrasib), and pan-KRAS(ON) inhibitors (RMC-6236, ASP3082) are in phase I/II trials covering G12D, G12V, and G12R. Testing matters now — because it determines trial eligibility.
The second myth: "If I am KRAS G12D, I should just wait for a drug."
Reality: Waiting is not a strategy. The actionable step today is to find the specific trial that is currently enrolling for your variant — not to wait for a future approval.
Key point: "KRAS mutant" is a category. "KRAS G12D with a specific co-mutation profile" is your actual case — and it is what trials enroll against.
Who This Page Is For — and Who It Is Not For
This page has one specific job. If you are here for something else, one of the other pages in the cluster will serve you better.
This page is for you if…
- You have a molecular report showing KRAS G12C, G12D, G12V, G12R, Q61, or wild-type — and want to understand what it actually means
- Your oncologist mentioned "KRAS" but you do not know what variant you are or what the difference is
- You want to know which targeted drugs are approved, which are in trials, and which are still research-only
- You want a checklist of questions to ask your oncologist before any treatment decision
This page is not for you if…
- You are looking for a country recommendation — see Clinical Trials in China
- You are looking for the full organoid testing process — see Patient-Derived Organoid Testing
- You are looking for how to obtain a second opinion — see Oncology Second Opinions
- You want us to tell you which drug to take — we do not; only your oncologist can decide that
What Patients Actually Ask When They Read Their KRAS Report
"My report said KRAS G12V. My oncologist said 'there is nothing approved for that.' For eight months I thought that meant I had no options. Only later I learned that G12V is one of the variants covered by pan-KRAS inhibitor trials. Nobody had explained the difference between 'approved' and 'in trials.' This page should have existed."— 59-year-old patient, metastatic PDAC, Tehran (identity withheld)
- What is my exact KRAS variant — G12C, G12D, G12V, G12R, Q61, or wild-type?
- Is there an approved drug for my variant today?
- If not, is there a trial currently enrolling for my variant?
- Does my variant affect my response to standard chemotherapy?
- What co-mutations (TP53, SMAD4, CDKN2A) matter alongside KRAS?
- If I start a KRAS inhibitor, what resistance mechanism should we monitor?
- Does my report include the information a trial would need?
KRAS Variants in PDAC — What Each One Means
Frequency, approved options, trial options, and the honest caveat for each variant.
| Variant | Frequency in PDAC | Approved therapy | In trials (2026) | Honest caveat |
|---|---|---|---|---|
| G12D | ~40% | None | pan-KRAS(ON) inhibitors (RMC-6236, ASP3082) — phase I/II | Most common variant. Largest need. Do not wait for approval — find trial now. |
| G12V | ~30% | None | Covered by pan-KRAS(ON) trials | Often confused with "no option" — it is a trial variant, not an approved one. |
| G12R | ~15% | None | Emerging coverage in newer pan-KRAS trials | Third most common. Trial access varies by geography. |
| G12C | ~1–2% | Sotorasib, Adagrasib | Combination trials (KRAS G12C + EGFR/MEK/SHP2) | Only variant with approved drugs. But single-agent response in PDAC is short — combinations are the frontier. |
| Q61 / G13 | ~5–10% | None | Weaker pan-KRAS coverage; alternative pathway trials (PI3K/AKT) | Underrepresented in trials. Organoid testing may inform selection. |
| KRAS wild-type | ~5–10% | Depends on the driver (BRAF, NRG1, NTRK, HER2) | Driver-specific trials | Wild-type is not "better" — it points to other targets. Broad NGS is essential. |
Important caveat on "approved" vs "in trials"
The fact that a drug is "in a trial" does not mean it will work. Pan-KRAS inhibitors are showing early signals in phase I/II — but the field has a long history of promising early data that did not translate to durable benefit in pancreatic cancer. The honest framing is: "trial" means "an option to discuss," not "an option that will work."
This page does not recommend any specific drug. It helps you ask better questions — so your oncologist can make a better clinical decision.
The 10-Question Checklist — What to Ask Your Oncologist Before Any KRAS-Targeted Decision
Print this, or bring it to your next appointment. If your oncologist cannot answer a question, ask who can — that is the referral you need.
The KRAS Report Reading Checklist
Ten questions to bring to your next oncology appointment — written in plain language, not medical jargon.
What is my exact KRAS variant?
Not just "KRAS mutant" — ask for the exact variant (G12C, G12D, G12V, G12R, Q61, G13, or wild-type). Ask for a copy of the molecular report so you can read it yourself.
Which co-mutations are present?
Ask about TP53, SMAD4, CDKN2A, BRCA1/2, and MSI/MMR status. Co-mutations affect both prognosis and trial eligibility.
Is there an approved drug for my variant?
Right now, only G12C has FDA-approved inhibitors (sotorasib, adagrasib). If you are not G12C, the answer is "no approved drug" — but "no approved drug" is not the same as "no option."
Is there a trial currently enrolling for my variant?
Ask: "Is there a pan-KRAS(ON) trial I qualify for?" — and ask for the trial identifier (NCT number) so you can verify it yourself on ClinicalTrials.gov.
Does my variant affect my response to standard chemotherapy?
Current evidence suggests KRAS variant alone does not change the choice of first-line chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) — but this is an active research question. Ask your oncologist for their view.
What does my report include — and what is missing?
A complete molecular report should include: variant allele frequency (VAF), co-mutations, MSI/MMR status, TMB, and (if relevant) HRD. If your report is missing these, ask for a broader NGS panel or a new biopsy.
If I start a KRAS inhibitor, what resistance mechanism should we monitor?
Secondary KRAS mutations, bypass pathway activation (EGFR, MET, SHP2), and histologic transformation are all documented. Ask what monitoring plan (ctDNA, imaging) your team will use.
Should I have functional (organoid) testing in addition to NGS?
Organoid testing asks a different question: not "what mutation do I have?" but "what does my tumor actually respond to?" See the Organoid Testing page →
Is a second opinion appropriate for my case?
If your variant is uncommon, or if your team has not discussed trials, a second opinion from a high-volume PDAC center is reasonable — not a sign of distrust. See the Second Opinion page →
If a trial is in another country, what would that involve?
Trial access abroad involves eligibility review, medical records translation, visa logistics, and time. The China trials page walks through this honestly. See Clinical Trials in China →
Frequently Asked Questions
Should every pancreatic cancer patient have KRAS testing?
Yes — for two reasons. First, ~90% of PDAC carries a KRAS mutation, and the exact variant determines trial eligibility. Second, the 5–10% who are KRAS wild-type have different actionable targets (BRAF, NRG1, NTRK, HER2, MSI-H) that a broad NGS panel will reveal. In both cases, testing changes the conversation.
Is G12C the only KRAS mutation with an approved drug?
As of October 2026, yes. Two G12C inhibitors — sotorasib and adagrasib — are FDA-approved for other cancers (NSCLC) and are used off-label or in trials for G12C PDAC. For G12D, G12V, G12R, Q61, and other variants, pan-KRAS(ON) inhibitors are in phase I/II trials, but none are approved yet. This is a rapidly evolving area — verify current status with your oncologist.
My report says "KRAS wild-type" — is that good news?
Not necessarily. "Wild-type" means no KRAS mutation was detected — which occurs in ~5–10% of PDAC. It is not "better." It means your tumor is driven by a different oncogene, and a broad NGS panel should look for BRAF V600E, NRG1 fusions, NTRK fusions, HER2 amplification, and MSI-H. Some of these have very effective targeted therapies — so wild-type is a reason to test more, not less.
How do I read my molecular report?
Ask your oncologist for the full report — not just the summary. Look for: (1) the exact KRAS variant, (2) the variant allele frequency (VAF) — what fraction of tumor cells carry it, (3) co-mutations (TP53, SMAD4, CDKN2A, BRCA1/2), (4) MSI/MMR status, (5) TMB — tumor mutational burden. If any of these is missing, ask whether a broader panel is appropriate. The 10-question checklist above is a starting point.
Does my KRAS variant change which chemotherapy I get?
Current evidence does not support changing first-line chemotherapy (FOLFIRINOX vs gemcitabine/nab-paclitaxel) based on KRAS variant alone. However, KRAS is an active area of research, and this may change. Ask your oncologist for their current view — and ask specifically whether your variant affects their recommendation.
Can I join a KRAS trial in my country, or do I need to travel?
Depends on your variant and your country. G12C trials exist in many countries. Pan-KRAS(ON) trials — covering G12D, G12V, G12R — are concentrated in the US, EU, China, and a few other countries. Travel is often required for less-common variants. The China Trials page walks through this honestly for the China option.
Why do you say "no approved drug" is not the same as "no option"?
Because in 2026, many PDAC patients with non-G12C variants are enrolling in pan-KRAS trials — and some are responding. "Approved" is a regulatory status, not a clinical ceiling. The right question is not "what is approved?" but "what is open and available for my exact variant right now?" That is what the checklist on this page helps you ask.
If Your KRAS Report Left You With More Questions Than Answers
We are not here to replace your oncologist — or to recommend a specific drug. If you have questions this page did not answer — about your specific variant, about trial eligibility, or about what to ask at your next appointment — you can share them with us.
We reply within 48 hours. If your variant is already clear and your oncologist has a plan, we will say so honestly.
Continue Your Pancreatic Cancer Research
This page is one of four focused resources. If your next question is about trials, testing, or expert review, these are the natural next pages.
Patient-Derived Organoid Testing
When NGS tells you the mutation but not the response — organoid testing asks a different question.
Learn about organoidsClinical Trials in China
How to identify relevant trials, review eligibility, and verify whether international patients can participate.
Explore China trialsOncology Second Opinions
How to seek an independent oncology opinion — and what records and molecular results a meaningful review requires.
Explore second opinionsReferences
- U.S. National Library of Medicine — ClinicalTrials.gov. Public registry of clinical studies. clinicaltrials.gov
- National Comprehensive Cancer Network (NCCN) — Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. nccn.org
- American Society of Clinical Oncology (ASCO) — Pancreatic Cancer treatment guidelines. asco.org
- U.S. Food and Drug Administration — Oncology drug approvals and labels. fda.gov
- European Medicines Agency — Oncology product information. ema.europa.eu
- PubMed — Biomedical literature database. pubmed.ncbi.nlm.nih.gov
- CancerCareE — Financial Transparency and Editorial Policy. cancercaree.com/financial-transparency/